Drug development & registration,
Год журнала:
2023,
Номер
12(2), С. 135 - 145
Опубликована: Май 28, 2023
Introduction.
SARS-CoV-2
(severe
acute
respiratory
syndrome-related
coronavirus
2)
is
expected
to
remain
a
persistent
global
threat.
Therefore,
development
of
disease
2019
(COVID-19)
drugs
the
most
urgent
issue.
Nirmatrelvir
and
ritonavir
combination
an
oral
antiviral
drug
with
activity
against
SARS-CoV-2.
highly
efficacious
in
reducing
risk
COVID-19.
The
study
describes
validation
high-performance
liquid
chromatography
–
tandem
mass
spectrometry
(HPLC-MS/MS)
method
for
simultaneous
determination
nirmatrelvir
human
blood
plasma.
could
be
applied
pharmacokinetic
ritonavir.
Aim.
aim
this
develop
validate
HPLC-MS/MS
bioanalytical
Materials
methods.
plasma
by
HPLC-MS/MS.
samples
were
processed
acetonitrile
protein
precipitation.
Internal
standard:
promethazine.
Mobile
phase:
0.1%
formic
acid
solution
water
(Eluent
A),
B).
Column:
Phenomenex
Luna
C18
50
×
2.0
mm,
5
μm.
Analytical
range:
50.00–10000.00
ng/mL
nirmatrelvir,
5.00–1000.00
Ionization
source
ionization:
electrospray
ionization,
positive.
Detection
conditions:
499.90
→
110.10
m/z,
319.20
m/z
(nirmatrelvir),
720.90
426.00
296.20
268.10
197.10
139.90
(ritonavir),
285.15
198.05
(promethazine).
Results
discussion.
This
was
validated
selectivity,
matrix
effect,
calibration
curve,
accuracy,
precision,
spike
recovery,
lower
limit
quantification,
carry-over
effect
stability.
Conclusion.
quantitative
developed
validated.
analytical
range
investigate
pharmacokinetics
Heliyon,
Год журнала:
2024,
Номер
10(15), С. e34820 - e34820
Опубликована: Июль 20, 2024
Aim
of
the
studyOur
hypothesis
is
that
nirmatrelvir
can
penetrate
blood‒brain
barrier
and
reach
effective
concentrations
in
brain.
Furthermore,
herbal
formulations
help
maintain
levels
body,
suggesting
potential
interactions
between
these
medications.Materials
methodsTo
investigate
this
hypothesis,
an
animal
model
combining
multisite
microdialysis,
ultrahigh-performance
liquid
chromatography
tandem
mass
spectrometry
(UHPLC-MS/MS)
methods
was
developed
to
monitor
blood
brain
rats.ResultsThe
pharmacokinetic
results
showed
area
under
curve
(AUC)
798.3
±
58.56
187.2
23.46
min
μg/mL,
respectively,
after
administration
alone
(15
mg/kg,
iv).
When
Scutellaria
baicalensis
were
administered
for
five
consecutive
days
prior
drug
administration,
AUC
increased.ConclusionsThese
provide
constructive
preclinical
information
greater
than
concentration
(EC90)
more
6
h,
had
synergistic
effects
by
increasing
blood.
Drug development & registration,
Год журнала:
2023,
Номер
12(2), С. 135 - 145
Опубликована: Май 28, 2023
Introduction.
SARS-CoV-2
(severe
acute
respiratory
syndrome-related
coronavirus
2)
is
expected
to
remain
a
persistent
global
threat.
Therefore,
development
of
disease
2019
(COVID-19)
drugs
the
most
urgent
issue.
Nirmatrelvir
and
ritonavir
combination
an
oral
antiviral
drug
with
activity
against
SARS-CoV-2.
highly
efficacious
in
reducing
risk
COVID-19.
The
study
describes
validation
high-performance
liquid
chromatography
–
tandem
mass
spectrometry
(HPLC-MS/MS)
method
for
simultaneous
determination
nirmatrelvir
human
blood
plasma.
could
be
applied
pharmacokinetic
ritonavir.
Aim.
aim
this
develop
validate
HPLC-MS/MS
bioanalytical
Materials
methods.
plasma
by
HPLC-MS/MS.
samples
were
processed
acetonitrile
protein
precipitation.
Internal
standard:
promethazine.
Mobile
phase:
0.1%
formic
acid
solution
water
(Eluent
A),
B).
Column:
Phenomenex
Luna
C18
50
×
2.0
mm,
5
μm.
Analytical
range:
50.00–10000.00
ng/mL
nirmatrelvir,
5.00–1000.00
Ionization
source
ionization:
electrospray
ionization,
positive.
Detection
conditions:
499.90
→
110.10
m/z,
319.20
m/z
(nirmatrelvir),
720.90
426.00
296.20
268.10
197.10
139.90
(ritonavir),
285.15
198.05
(promethazine).
Results
discussion.
This
was
validated
selectivity,
matrix
effect,
calibration
curve,
accuracy,
precision,
spike
recovery,
lower
limit
quantification,
carry-over
effect
stability.
Conclusion.
quantitative
developed
validated.
analytical
range
investigate
pharmacokinetics
